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Introduction
Within the past several years, there have been major advances 
in the treatment of metastatic melanoma, including the use of 
therapeutics that specifically target oncogenic mutations such as 
alterations in BRAF. Mutations in BRAF indeed occur in near 
half of melanoma cases.1,2 The treatment of patients with mela-
noma harboring BRAF mutations results in a large proportion of 
objective responses, and several agents targeting mutant BRAF 
are now approved for use in individuals with stage IV disease.3,4 
However, despite dramatic initial responses, the majority of mel-
anoma patients do not achieve a durable response upon treat-
ment with BRAF inhibitors (BRAFi), with disease progression 
occurring within several months after the initiation of therapy 
(generally, 6 mo for BRAFi monotherapy, 10 mo when BRAFi 
are combined with MEK inhibitors).4,5 Alternative therapeutic 
strategies to achieve long-term clinical responses are therefore 
urgently needed.
Compelling evidence indicates that oncogenic BRAF muta-
tions contribute to the immune escape of malignant cells and that 
targeting this pathway may increase the immunogenicity of mela-
noma. The initial evidence in support of this notion came from in 
vitro studies demonstrating that the administration of a BRAFi is 
associated with an augmentation in melanoma-associated antigens 
as well as with an increased reactivity of antigen-specific T cells.6 
More recently, these findings were corroborated in melanoma 
patients treated with BRAFi, who exhibited not only an increase 
in melanoma-associated antigens but also a rather therapy-friendly 
tumor microenvironment, containing decreased levels of immu-
nosuppressive cytokines and vascular endothelial growth factor 
(VEGF).7-9 Importantly, we and others have reported a significant 
increase in tumor-infiltrating CD8+ T cells within 10–14 d of 
the administration of a BRAF inhibitor.7,10 Taken together, these 
observations suggest a potential synergy between BRAF-targeted 
agents and immunotherapeutic strategies against melanoma, 
though several important questions remain unanswered.
*Correspondence to: Jennifer A Wargo; Email: jwargo@mdanderson.org
Submitted: 07/31/2013; Revised: 09/24/2013; Accepted: 09/26/2013
Citation: Cooper ZA, Frederick DT, Juneja VR, Sullivan RJ, Lawrence DP, Piris A, Sharpe AH, Fisher DE, Flaherty KT, Wargo JA. BRAF inhibition is associated with 
increased clonality in tumor-infiltrating lymphocytes. OncoImmunology 2013; 2:e26615; http://dx.doi.org/10.4161/onci.26615
BRAF inhibition  
is associated with increased clonality  
in tumor-infiltrating lymphocytes
Zachary a Cooper1,2, Dennie T frederick3, Vikram r Juneja4,5, ryan J Sullivan6,7, Donald P Lawrence6,7, 
adriano Piris7,8, arlene H Sharpe4, David e fisher7,9, Keith T flaherty6,7, and Jennifer a Wargo1,2,*
1Department of Surgical Oncology; University of Texas MD anderson Cancer Center; Houston, TX USa;  
2Department of Genomic Medicine; University of Texas MD anderson Cancer Center; Houston, TX USa; 3Division of Surgical Oncology; Massachusetts General Hospital; 
Boston, Ma USa; 4Department of Microbiology and Immunobiology; Harvard Medical School; Boston, Ma USa; 5Division of Health Sciences and Technology; Massachusetts 
Institute of Technology; Cambridge, Ma USa; 6Division of Medical Oncology; Massachusetts General Hospital; Boston, Ma USa; 7Harvard Medical School; Boston, Ma 
USa; 8Division of Dermatopathology; Massachusetts General Hospital; Boston, Ma USa; 9Division of Dermatology; Massachusetts General Hospital; Boston, Ma USa
Keywords: BRAF; melanoma; T cells; TILs; vemurafenib
There have been significant advances with regard to Braf-targeted therapies against metastatic melanoma. How-
ever, the majority of patients receiving Braf inhibitors (Brafi) manifest disease progression within a year. We have 
recently shown that melanoma patients treated with Brafi exhibit an increase in melanoma-associated antigens and in 
CD8+ tumor-infiltrating lymphocytes in response to therapy. To characterize such a T-cell infiltrate, we analyzed the com-
plementarity-determining region 3 (CDr3) of rearranged T-cell receptor (TCr) β chain-coding genes in tumor biopsies 
obtained before the initiation of Brafi and 10–14 d later. We observed an increase in the clonality of tumor-infiltrating 
lymphocytes in 7 of 8 patients receiving Brafi, with a statistically significant 21% aggregate increase in clonality. Over 
80% of individual T-cell clones detected after initiation of Brafi treatment were new clones. Interestingly, the compari-
son of tumor infiltrates with clinical responses revealed that patients who had a high proportion of pre-existing domi-
nant clones after the administration of Brafi responded better to therapy than patients who had a low proportion of 
such pre-existing dominant clones following Brafi. These data suggest that although the inhibition of Braf in mela-
noma patients results in tumor infiltration by new lymphocytes, the response to treatment appears to be related to the 
presence of a pre-existing population of tumor-infiltrating T-cell clones.e26615-2  OncoImmunology  Volume 2 Issue 10
Indeed, it is still unclear whether the BRAFi-dependent 
increase in tumor infiltration originates from the necrotic demise 
of malignant cells or rather reflects the elicitation of a primary 
immune response involving antigen-specific T cells. Based on the 
observations reported above, we hypothesized that the immune 
infiltrate associated with BRAFi would constitute a primary 
response, and that the administration of a BRAFi would increase 
the clonality of tumor-infiltrating lymphocytes (TILs). However, 
the analysis of TILs by techniques such as flow cytometry in our 
patient population was prevented by the limited availability of 
tumor biopsies, especially after the initiation of BRAF-targeted 
therapy. To circumvent this limitation, we utilized a multiplex 
PCR strategy to amplify the CDR3 region of the T-cell receptor 
(TCR) β chain-coding gene, spanning the variable region formed 
by the junction of the V, D, and J segments and their associ-
ated non-templated insertions.11 The resulting 60-bp nucleotide 
sequence could be used as an identifier or “tag” for a particular 
clone across different samples. In 8 metastatic melanoma patients 
harboring BRAF mutations, we sequenced the CDR3 region in 
tumor biopsies obtained before treatment (day 0) and 10–14 d 
after the initiation of BRAF-targeted therapy). The goal of the 
present study was to better define the T-cell infiltrate elicited by 
BRAFi and hence allow for the development of therapeutic strat-
egies that specifically harness BRAFi-induced tumor infiltration.
Results
We (and others) have previously shown that BRAF inhibi-
tion is associated with a significant increase in tumor-infiltrating 
CD8+ T cells within 10–14 d of treatment.7,10 In order to investi-
gate the clonality of BRAFi-elicited TILs and gain insights into 
the antigen specificity of such a T-cell response, we sequenced the 
variable CDR3 region in serial biopsies collected before treatment 
and 10–14 d after the initiation of BRAF-targeted therapy from 
8 metastatic melanoma patients harboring BRAF mutations. 
The age of these individuals ranged from 25 to 72 y and patients 
had multiple sites of disease (Table 1). All patients manifested a 
decrease in the size of targeted lesions after the administration 
of BRAF inhibitors, as assessed by radiographical methods. In 
particular, 5 patients achieved a partial response, 1 manifested a 
complete response and 2 exhibited stable disease (Fig. 1; Table 1).
Treatment with BRAFi increases TIL clonality but does not 
alter the overall proportion of dominant clones
The TIL clonality, a term used to quantify the diversity of 
clones and frequency of any given clone, was determined using 
a software provided by Adaptive Biotechnologies. The equation 
to calculate clonality is 1-(entropy)/log2(# of productive unique 
reads), where the entropy term takes into account the variation of 
clone frequencies. In this setting, a maximally diverse cell popu-
lation in which every sequence is represented one time would be 
associated with a clonality score of 0, and a perfectly monoclonal 
population (a theoretical situation approached in some patients 
with chronic lymphocytic leukemia) would obtain a clonality 
score of 1. Using the technique described above, we analyzed the 
clonality of our samples and observed a significant increase in 
TIL clonality upon BRAFi-based therapy in 7 out of 8 patients 
(Fig. 2A). Importantly, we wanted to determine if the increase 
in clonality correlated with response to treatment. To do this, we 
first took into consideration the dominant clones, i.e., the clones 
that make up the largest percentage of the total T-cell population, 
in patients under treatment with BRAFi. We sorted these clones 
by frequency, each clone being listed once, focused on the top 5% 
of them, and asked what percentage of the overall T-cell popula-
tion these clones represented. We determined that the top 5% of 
clones represented between 40–60% of the overall T-cell popu-
lation, but no correlation existed between these values and the 
response of melanoma patients to therapy. Similarly, we observed 
no correlation with disease outcome when we performed this 
analysis for the top 2.5%, 1%, or 0.5% of clones (Fig. 2B).
BRAFi-based therapy results in new TIL clones in patients 
with metastatic melanoma
Next, we wanted to see if the increase in clonality elicited by 
BRAFi in melanoma patients was associated with the infiltration 
of neoplastic lesion by novel TIL clones. To this aim, we analyzed 
the biopsies obtained from patients on BRAF inhibitors for the 
presence of clones that were absent from pre-treatment biopsies. 
Interestingly, ~80% of the individual clones detected in the biop-
tic samples from treated patients were shown to be new clones, 
suggesting that there is a considerable influx of T cells within 
the neoplastic lesions of melanoma patients treated with BRAFi 
(Fig. 3A).
The clinical response to BRAFi is associated with a pre-
existing population of TIL clones
To further understand the role of TIL clones in therapeutic 
efficacy of BRAFi, we focused on the top 5%, 2.5%, 1%, or 
0.5% dominant clones found in the biopsies of treated patients 
and examined whether these clones were present within neoplas-
tic lesions before the initiation of therapy. We then correlated 
the percentage of pre-existing dominant clones with the clinical 
response to BRAFi. Two groups clearly emerged: patients with a 
high proportion of pre-existing dominant clones after the admin-
istration of BRAFi exhibited a good response, whereas patients 
who had a low proportion of such clones on treatment had poor 
disease outcome (Fig. 3B). Specifically, the 3 patients with the 
lowest proportion of pre-existing dominant clones exhibited the 
poorest responses of the whole cohort at all time points measured 
(Fig. 1 and 3B). Of note, there was no clear correlation between 
the proportion of pre-existing dominant clones upon BRAFi-
based therapy and progression-free survival, though the number 
of patients analyzed was admittedly low. Overall, these data sug-
gest that the response to BRAFi may correlate with the presence 
of pre-existing dominant T-cell clones, and perhaps also that pre-
existing TIL populations may be more important than new TILs 
in the elicitation of therapeutically-relevant immune responses by 
BRAF-targeting therapies.
Discussion
The profound clinical response of metastatic melanoma 
patients to BRAFi demonstrates a significant advance in cancer 
therapeutics. Although transient, such a response is indeed asso-
ciated with an increase in melanoma-associate antigens and TILs www.landesbioscience.com OncoImmunology  e26615-3
as well as with tumor microenvironment that supports the effects 
of therapy.7-10 Interestingly, 95.3% of patients manifest a decrease 
in disease burden upon treatment with BRAFi, but only 43% 
display an objective response.3 Although numerous mechanisms 
of resistance to BRAFi have been described (including BRAF 
mutations, splice isoforms, copy number alterations, fusions, and 
allele specific expression),12-23 differences in the immune response 
elicited by BRAF inhibition have not been well studied. A better 
understanding of the immunological mechanisms triggered by 
BRAFi could help us to explain the diversity in both maximal 
response to therapy and progression free survival of melanoma 
patients subjected to BRAF-targeting therapies, and may have 
significant translational implications.
Here, we analyzed the clonality of TILs in melanoma 
patients on BRAFi. Importantly, the patients included in this 
study include objective responders and non-responders, both 
groups demonstrating an increase in T-cell infiltrate. However, 
differences were seen between these groups of patients when we 
looked deeply into the origin of the T-cell clones that infiltrated 
neoplastic lesions in response to BRAFi.
T-cell clonality can be studied by observing changes in the 
variable V, D, J region of the CDR3-coding sequence within 
tumor biopsies. This variable region plays a critical role in deter-
mining antigen specificity.24,25 Our results confirms previous 
findings from Yazdi et al., who used laser-capture micro-dissec-
tion to isolate different TIL clusters and demonstrated that many 
T-cell clones with different TCR rearrangements may be detected 
within one primary malignant melanoma.26 The significant 
increase in aggregate clonality upon the administration of BRAFi 
suggests that other factors are involved in response to treatment. 
The kinetics of such an increase in clonality (after 10–14 d) is 
not surprising, as Buchholz et al. have shown that a spectrum 
of T-cell expansion kinetics exists, ranging from slow-dividing, 
long-lived T cells to fast-proliferating, short-lived cell subsets in 
Figure 1. Tumor burden in melanoma patients treated with Braf inhibitors. The size of neoplastic lesions (assessed the longest linear dimension) in 
melanoma patients receiving Braf inhibitors (Brafi) is plotted against time. The horizontal dashed line indicates a decrease of 30% in target lesion size, 
which demarks an “objective response” according to the response evaluation Criteria in Solid Tumors (reCIST), version 1.1.32 Solid data points refer to 
patients who are currently on trial, clear data points to individual that dropped out of the study. red triangles mark time-to-progression. Patient 24 was 
on commercial drugs so official assessment of tumor burden were not performed.
Table 1. Patient characteristics
ID# Age Gender Site Treatment Response PFS (months)
7 56 M n, sc Brafi + MeKi Cr (100%) 18
9 36 M br, n Brafi + MeKi Pr (-45%) 7
10 37 f li, n, sc Brafi + MeKi SD (-13%) 3
11 72 M br, sc Brafi + MeKi Pr (-80%) 10
14 25 M b, n, sc, lu Brafi + MeKi Pr (-64.9%) 8
16 43 M n, sc Brafi + MeKi SD (-19.5%) 11
19 61 M lu, n, sc Brafi + MeKi Pr (-48.7%) 13, ongoing
24 70 f br, li, lu, n, sc Brafi Pr (-53%) 2
Patients with metastatic melanoma harboring BRAFV600E (confirmed by genotyping) were enrolled in clinical trials and treated with 
a Braf inhibitor (Brafi) alone or combined with a MeK inhibitor (Brafi + MeKi). abbreviations: B, bone; br, brain; Cr, complete 
response; li, liver; lu, lung; n, nodal; PfS, progression-free survival; Pr, partial response; sc, subcutaneous; SD, stable disease.e26615-4  OncoImmunology  Volume 2 Issue 10
which a single T lymphocyte can lead to 70,000 descendants in 
infection models.27
In our small cohort of patients, there was a striking differ-
ence in the relationship between the maximal response to therapy 
and the presence of new dominant clones. This suggests that the 
response to BRAFi may rely on pre-existing TILs rather than on 
the infiltration of neoplastic lesions by new T-cell clones. The 
specificity of this clonal response requires further investigation. 
The increase in clonality observed herein may be suggestive of an 
antigen-specific response, though there are several obstacles to 
answering this question definitively. First, the amount of biop-
tic material (especially in the case of treated patients) is quite 
limited, implying that conventional methods to assess an anti-
gen-specific response such as tetramer staining could not be per-
formed. Moreover, use of technical platforms such as ELISPOT 
requires a step of in vitro stimulation, which may significantly 
alter the clonal composition of TILs. Finally, in line with the nov-
elty of the TCR sequencing approach used in this manuscript, we 
could not rely on a data set describing the antigen specificity of 
each particular TCR. Such data sets, allowing for the determina-
tion of antigen specificity, may become available in the future, 
along with the diffusion of this technology.
The influence of the anatomical site of disease on TIL clon-
ality is not well understood, and our data do not completely 
address this question. The majority of biopsies taken in the con-
text of this study were from cutaneous or subcutaneous lesions, 
and only a few of them from other sites (e.g., lymph nodes). 
The precise characterization of TCR clonality in cutaneous vs. 
visceral sites of disease may provide further insights to this issue. 
Another interesting question is whether the diversity of TIL 
clonality is expected between distinct biopsy sites or whether 
it is due to BRAFi. Our data suggest that this diversity is due 
to BRAF inhibition, although to definitively answer this ques-
tion one would need to obtain serial biopsies of the same and 
different lesions from the same patient (both before treatment 
and in the course of BRAF-targeting therapy), which would be 
challenging.
Many other questions arise with our data. What is the pre-
existing TIL population and why is it present in some patients 
and not in others? Is it an expansion of such a pre-existing popu-
lation or an activation of an already dominant yet exhausted pop-
ulation of T cells that mediate therapeutic responses to BRAFi? Is 
the presence of pre-existing TILs in the lesions of treated patients 
paralleled by a circulating biomarker that may represent an early 
indicator of response to therapy?
Of note, we have previously observed a deleterious effect of 
MEK inhibition on T lymphocytes in vitro, raising the con-
cern that MEK inhibitors may alter T-cell function in patients.6 
However, we observed no significant difference in the absolute 
number of CD8+ TILs between patients receiving BRAFi alone 
or a BRAFi plus a MEK inhibitor,7 although functional studies 
on these cells were not performed. These preliminary data sug-
gest that MEK inhibition does not significantly impact T-cell 
function in patients. In line with our findings, Shindo et al. 
demonstrated that MEK inhibitors selectively suppress the allo-
reactivity of naïve T cells in the course of graft-vs.-host-disease 
without a significant effect on the memory T-cell population.28 
This suggests that MEK inhibitors may have a less pronounced 
Figure 2. Braf inhibitors increase the clonality of tumor-infiltrating lymphocytes. (A) Changes in clonality of tumor-infiltrating lymphocytes (TILs) 
10–14 d after the initiation of Braf inhibitors are shown as fold change as compared with pre-treatment values, as a box and whiskers plot (n = 8 
patients). The bottom and top of the box represent the 25th and 75th percentile, respectively, while the bar indicates the median value. (B) Percentage 
of the total TIL population occupied by the 5%, 2.5%, 1%, and 0.5% dominant TIL clones. Patient samples are sorted along the X-axis based on their 
maximal response to treatment. Cr, complete response; Pr, partial response; SD, stable disease.www.landesbioscience.com OncoImmunology  e26615-5
effect on memory T cells than on their naïve counterparts. CD8+ 
TILs are expected to comprise a significant fraction of antigen-
experienced memory cells, and may therefore be rather insensitive 
to MEK inhibition. To date, this hypothesis has not been tested.
Additional translational implications of our findings relate 
to recent advances in the treatment of melanoma patients with 
immune checkpoint inhibitors, such as monoclonal antibod-
ies specific for cytotoxic T lymphocyte-associated protein 4 
(CTLA4), programmed cell death 1 (PDCD1, best known as 
PD-1) and CD274 (best known as PD-L1).29-31 The characteriza-
tion of TIL populations along the lines of our study may provide 
insights into the propensity of patients to respond to this form of 
immunotherapy. In addition, this approach may provide a ratio-
nale for combination immune checkpoint blockers and BRAFi.
This is the first report to study the clonality of the T-cell 
infiltrate in melanoma patients treated with BRAFi and its 
correlation with disease outcome. Given the small number of 
patients involved in this study, we look forward to other groups 
testing our conclusions in independent patient cohorts, a work 
that is currently underway.
Materials and Methods
Patient samples
Metastatic melanoma patients harboring the BRAFV600E muta-
tion (confirmed by genotyping) were enrolled in a clinical trial 
at Massachusetts General Hospital and treated with a BRAFi 
alone (vemurafenib) or combined with a MEK inhibitor (dab-
rafenib + trametinib) (Table 1). Tumor biopsies were obtained 
before treatment (day 0) and 10–14 d after treatment initiation. 
Formalin-fixed tissues were analyzed to confirm the presence of 
viable tumor cells upon hematoxylin and eosin (H&E) staining. 
Figure 3. a high proportion of pre-existing clones within the dominant T-cell population after the administration of Braf inhibitors correlates with 
improve response to treatment. (A) The percentage of new T-cell clones infiltrating neoplastic lesions after the administration of Braf inhibitors (Brafi) 
was determined by comparing the presence of a tumor-infiltrating lymphocyte (TIL) in biopsies taken before treatment and 10–14 d after the of therapy. 
Individual patient data are presented with the mean ± SeM for the entire patient cohort (n = 8). (B) Percentage of the top 5%, 2.5%, 1%, and 0.5% domi-
nant TIL clones that were present before the inhibition of therapy. Patient samples are sorted along the X-axis based on their maximal response to treat-
ment. Cr, complete response; Pr, partial response; SD, stable disease.e26615-6  OncoImmunology  Volume 2 Issue 10
Tissues were immediately processed for genomic DNA extrac-
tion. Explicit consent on the procedure was obtained as per the 
institution review board-approved protocol.
Preparation of genomic DNA
Clinical samples were received in the form of tumor tissue. 
For DNA purification, tissue was digested overnight at 55°C in 
extraction buffer (10 mM Tris pH 8.0, 25 mM EDTA, 0.5% 
sodium dodecyl sulfate, 100 mM NaCl) supplemented with 
20 mg/mL proteinase K. Residual debris were removed by the 
addition of 80 μL of Protein Precipitation Solution (Promega 
#A795A) and centrifugation. Genomic DNA was precipitated 
by adding an equal volume of isopropanol. The DNA pellet was 
washed with 70% ethanol, air-dried and re-dissolved in sterile 
water.
CDR3 sequencing and clonality
CDR3 regions were sequenced on an Illumina HiSeq sequencer 
with at least 5-fold coverage by ImmunoSEQ™ sequencing 
(Adaptive Biotechnologies). The sequencing assay relies on a 
multiplex PCR reaction with forward primers annealing to each 
V segment and reverse primers annealing to each J segment, 
resulting in the selective amplification of rearranged VDJ seg-
ments from each cell in a format compatible with sequencing.11 
Clonality scores were calculated for our patient samples using a 
software by Adaptive Technologies, clonality being defined as 
1-(entropy)/log2(# of productive unique sequences), where the 
entropy term takes into account of the varying clone frequency. 
Clonality values are given through the ImmunoSeq Analyzer 
software, according to which a maximally diverse population is 
associated with a clonality score of 0 and a perfectly monoclonal 
population with a clonality score of 1. Analyzing the clones as 
a percent of total was performed to control for the number of 
unique reads in each specific patient sample.
Statistics
Statistical analyses were performed using the GraphPad Prism 
software or the R statistical package.
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